Abstract 110P
Background
Conversion therapy is an important treatment for patients with initial unresectable metastatic colorectal cancer(mCRC) to achieve radical resection. Circulating tumor cells (CTC) are one of the important liquid biopsy methods. There is no study to explore their clinical value in predicting the efficacy. The aim of this study is to explore the value of the number and morphology of CTC in predicting the efficacy of conversion therapy in initial unresectable mCRC patients.
Methods
This study prospectively collected eligible patients with initially unresectable mCRC who were initially diagnosed in Zhongshan Hospital from November 2020 to June 2021. At baseline, after treatment, and before and after conversion resection, multi-point blood sampling was performed. CTC detection using ChimeraX ® Platform; Morphological typing is based on the CTC morphological data of 2083 patients with colorectal cancer who underwent CTC detection in Zhongshan Hospital. Cell Profiler is used for cell feature assignment, clustering and typing.
Results
A total of 126 eligible patients with mCRC participated in this study. According to morphology, CTC can be divided into four morphological types: T1-T4. All 126 patients underwent baseline CTC testing, and 103 patients underwent CTC testing after conversion therapy. After conversion therapy, the positive rate and detection number of CTC significantly decreased (85.7% vs 60.2%, 1.71 vs 1.15, P=0.0052); The detection number of T3 and T4 subtypes significantly decreased (T3: 0.87 vs 0.52, P=0.0026, T4: 0.25 vs 0.06, P<0.0001). The objective response rate was significantly correlated with the baseline number of CTCs (69.8% vs 50.8%, P=0.029), but not significantly with the number of CTCs after treatment. The objective response rate of patients with T3T4 dominance was significantly higher than that of patients with T1T2 dominance (67.6% vs 47.1%, P=0.042). The number of CTC was correlated with patient progression free survival, and baseline CTC positive patients had a worse prognosis (P=0.0012).
Conclusions
The number and morphology of CTCs have good therapeutic and prognostic value for patients with initial unresectable mCRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract